Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.
The pharmacokinetics of teicoplanin after single 6-mg/kg intravenous and intraperitoneal doses were studied in five noninfected patients undergoing continuous ambulatory peritoneal dialysis. Biological samples were assayed for teicoplanin content by a microbiological assay technique. Terminal disposition half-life (266.4 +/- 51.9 h [mean +/- standard error of the mean]) was prolonged and total body clearance (0.040 +/- 0.004 ml/min per kg) was reduced compared with values previously reported in subjects with normal renal function. The volume of distribution at steady state (1.15 +/- 0.19 liters/kg) was higher than values previously reported in subjects with normal renal function (0.56 to 0.72 liter/kg). Peritoneal dialysis clearance (0.007 +/- 0.001 ml/min per kg) accounted for only 16.1% of total body clearance. The absolute systemic bioavailability of teicoplanin after intraperitoneal administration was 81.5 +/- 10.7%.
Guay
D R
DR
Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis, Minnesota.
Awni
W M
WM
Halstenson
C E
CE
Kenny
M T
MT
Keane
W F
WF
Matzke
G R
GR
D006020:Glycopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics; D006207:Half-Life; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D010531:Peritoneal Dialysis, Continuous Ambulatory; D017334:Teicoplanin
D006020:Glycopeptides; D017334:Teicoplanin